Literature DB >> 8089288

Interferon therapy for Behçet's disease.

E Alpsoy1, E Yilmaz, E Başaran.   

Abstract

BACKGROUND: Behçet's disease was first described in 1937 as a trisymptom complex. No standard therapy has been established. Its cause is presumed to be viral or immunologic.
OBJECTIVE: We sought to determine whether patients with Behçet's disease benefit from interferon, which has antiviral, immunomodulatory, antiproliferative, and antitumoral properties.
METHODS: Fourteen patients were initially given 3 MU interferon alfa-2a subcutaneously three times per week. The doses were gradually increased to 12 MU. Each patient received a total dose of 216 MU during the 2-month study. Therapy with 9 MU interferon alfa-2a once a month was continued in half the patients. All patients were observed before and after treatment for 6-month periods, and all symptoms were recorded.
RESULTS: All patients were symptom free by the end of the 2-month treatment period. The frequencies of oral and genital ulcers as well as pustular vasculitis decreased significantly in the posttreatment period as compared with the pretreatment period.
CONCLUSION: The data suggest that interferon treatment appears to be effective for patients with Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8089288     DOI: 10.1016/s0190-9622(94)70226-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

Review 1.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 2.  [Adamantiades-Behcet's disease].

Authors:  L Krause
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

Review 3.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

4.  Transverse myelitis in a patient with Behcet's disease: favorable outcome with a combination of interferon-alpha.

Authors:  Meral Calgüneri; Ahmet Mesut Onat; M Akif Oztürk; Levent Ozçakar; Kemal Ureten; Ali Akdogan; Ihsan Ertenli; Sedat Kiraz
Journal:  Clin Rheumatol       Date:  2004-10-26       Impact factor: 2.980

5.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

Review 6.  Behçet Disease: An Update for Dermatologists.

Authors:  Erkan Alpsoy; Burcin Cansu Bozca; Asli Bilgic
Journal:  Am J Clin Dermatol       Date:  2021-06-01       Impact factor: 7.403

Review 7.  Update on the treatment of Behçet's syndrome.

Authors:  Sinem Nihal Esatoglu; Gulen Hatemi
Journal:  Intern Emerg Med       Date:  2019-01-25       Impact factor: 3.397

Review 8.  Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.

Authors:  Cinzia Rotondo; Giuseppe Lopalco; Florenzo Iannone; Antonio Vitale; Rosaria Talarico; Mauro Galeazzi; Giovanni Lapadula; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2015-06-22       Impact factor: 4.711

9.  Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet's Syndrome with refractory vascular or neurological involvement: a case series.

Authors:  Luxi Sun; Yunxia Hou; Lifan Zhang; JinJing Liu; Lu Li; Zhimian Wang; Xin Yu; Menghao Zhang; Xiaoqing Liu; Yan Zhao; Wenjie Zheng
Journal:  Ther Adv Chronic Dis       Date:  2022-07-26       Impact factor: 4.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.